Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat

Experimental Neurology

Volumn 155, Issue 1, 1999, Pages 42-48

  Nash, Joanne E ^a   Hill, Michael P ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

NMDA receptor; NR2B selective NMDA receptor antagonists; Parkinson's disease; Reserpine treated rat model of Parkinson's disease; Striatum

Indexed keywords

DIZOCILPINE; DOPAMINE; ELIPRODIL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYAMINE; RESERPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOBUS PALLIDUS; LOCOMOTION; MALE; MEMBRANE BINDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BLOCKING;

EID: 0032966426     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6963     Document Type: Article

References (46)

1. 3Nd. J. Neurochem. 57:1991;39-45.
2. Beart P. M., Ryan M. C., Mercer L. D., Jarrott B., Wong M. G. Heterocyclic amino alcohols related to ifenprodil as a receptor ligand: Binding and conformational analysis. Eur. J. Pharmacol. 269:1994;193-200.
3. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Brotchie J. M., Mitchell I. J., Sambrook M. A., Crossman A. R. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6:1991;133-138.
5. Carlsson M., Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm. 77:1989a;65-71.
6. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989b;221-226.
7. Carlsson M., Svensson A. Interfering with glutamatergic transmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol Biochem. Behav. 36:1990a;45-50.
8. Carlsson M., Svensson A. The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci. 47:1990b;1729-1736.
9. Carlsson M. L. Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis). J. Neural Transm. Gen. Sect. 94:1993;1-10.
10. Carroll C. B., Holloway V., Brotchie J. M., Mitchell I. J. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for the treatment of parkinsonian symptoms. Psychopharmacology. 119:1995;55-65.
11. Chenard B. L., Shalaby I. A., Koe B. K., Ronall R. T., Butler T. W., Prochniak M. A., Schmidt A. W., Fox C. B. Separation of alpha 1 adrenergic and NMDA antagonist activity in a series of ifenprodil compounds. J. Med. Chem. 34:1991;3085-3090.
12. Cotzias G. P., Papavasiliou P. S., Gellene R. Modification of parkinsonism - Chronic treatment withl. N. Engl. J. Med. 280:1969;337-345.
13. Crossman A. R. Neural mechanisms in disorders of movement. Comp. Biochem. Physiol. 93:1989;141-149.
14. Griffiths P. D., Sambrook, Pan H. S., Young A. B., Penny J. B. γ-Aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem. 45:1991;1396-1404.
15. Hornykiewcz O. Dopamine and brain function. Pharmacol. Rev. 18:1966;925-964.
16. Kannari K., Markstein R. Dopamine agonists potentiate anti-akinetic effects of competitive NMDA-antagonists in monoamine-depleted mice. J. Neural Trans. Gen. Sect. 84:1991;211-220.
17. Klockgether T., Turski L. NMDA antagonists potentiate anti-parkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
18. Klockgether T., Turski L., Loschmann P. A., Wachtel H. Nd. Amino Acids: Chemistry, Biology and Medicine. 1990;ESCOM, Leiden. p. 269-674.
19. Klockgether T., Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34:1993;585-593.
20. Kutswada T., Kashiwabushi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M., Mishini M. Molecular diversity of the NMDA receptor channel. Nature. 358:1992;36-41.
21. Kuryatov A., Laube B., Betz H., Kuhse J. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron. 12:1994;1291-1300.
22. 3. Neuropharmacology. 54:1995;621-629.
23. Menegoz M., Lau L. F., Herve D., Huganir R. L., Girault J. A. Tyrosine phosphorylation of NMDA receptors in rat striatum: Effects of 6-OHDA Lesions. Neuroreport. 7:1995;125-128.
24. Miller W. C., DeLong M. R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. Carpenter M. B., Jayaraman A. The Basal Ganglia II. 1987;415-427 Plenum, New York.
25. Mitchell I. J., Cross A. J., Sambrook M. A., Crossman A. R. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contribution of the striatopallidal and striatonigral pathways are suggested by 2-deoxyglucose uptake. Neurosci. Lett. 63:1986;61-65.
26. Mitchell I. J., Hughes N., Carroll C. B., Brotchie J. M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol. 6:1995;492-507.
27. Miyoshi R., Kito S., Doudou N., Nomoto T. Influence of age on Nd. Synapse. 8:1991;212-217.
28. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeell H., Burnashev N., Sakmann B., Seeburg P. H. Heteromeric NMDA receptor: Molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
29. Nankai M., Fage D., Carter C. NMDA receptor subtype selectivity: Eliprodil, polyamine spider toxins, dextromexthorphan and desipramine selectivity block NMDA evoked acetylcholine but not spermidine release. J. Neurochem. 64:1993;2043-2048.
30. Nash J. E., Brotchie J. M. Anti-Parkinsonian Effect of NR2B-Selective NMDA Antagonists: A Striatal Mechanism of Action. Abstract Brain Res. Assoc. 14:1997;7.09.
31. Nash J. E., Fox S. H., Henry B., Hill M. P., Hille C. J., Maneuf Y. P., Peggs D., McGuire S., Crossman A. R., Brotchie J. M. Anti-Parkinsonian Effect of NMDA Antagonists in Animal Models of Parkinson's Disease: A Striatal Mechanism of Action. Abstract Soc. Neurosci. 23:1997;79.5.
32. 143. J. Neurochem. 62:1994;1835-1839.
33. Pan H. S., Young A. B., Penny J. B. γ-Aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem. 45:1985;1396-1404.
34. Papa S. M., Engber T. M., Kask A. M., Chase T. N. Motor fluctuations in levodopa treated parkinsonian rats relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
35. Quinn N., Critchley P., Marsden C. D. Young onset Parkinson's disease. Mov. Disord. 2:1987;73-91.
36. Reynolds I. J. Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor. Eur. J. Pharmacol. 177:1990;215-216.
37. Sanders K. H., Jurna I. Effects of urapidil, clonidine, prazocine and propranalol on autonomic nerve activity, blood pressure and heart rate in anaesthetised rats and cats. Eur. J. Pharmacol. 110:1985;181-190.
38. 3. Jap. J. Pharmacol. 59:1991;443-448.
39. Standaert D. G., Testa C. M., Hollinsworth Z., Young A. B., Penney J. B. Organisation of Nd. J. Comp. Neurol. 343:1994;1-16.
40. 112. Eur. J. Pharmacol. 250:1993a;239-246.
41. Starr M. S., Starr B. S. Glutamate antagonists modify the motor stimulate actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with mixed D1/D2 agonist apomorphine. J. Neural Transm. Park. Dis. Dement. Sect. 6:1993b;215-226.
42. 12. Psychopharmacology. 114:1994;469-476.
43. Steinfels G. F., Alberia G. P., Tam S. W., Cook L. Biochemical, behavioural and electrophysiological actions of the selective sigma receptor ligand, (+)-pentazocine. Neuropsychopharmacol. 1:1988;321-327.
44. Svensson A., Carlsson M. Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induced locomotor stimulation. Neuropharmacology. 31:1992;513-518.
45. Svensson A., Carlsson M. L., Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: Evidence for a dual glutamatergic function with respect to psychomotor control. J. Neural. Transm. Gen. Sect. 88:1992;235-240.
46. Williams K. Ifenprodil discriminates subtype of the N-methyl-D-aspartate receptors: Selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44:1993;851-859.